STAA earnings analysis
What we found in STAA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
STAAR reported $93.5 million of revenue, ahead of the $90.6 million consensus estimate, with gross margin of 74.5% and operating margin of 10.8%. EPS improved to $0.16 but missed the $0.19 estimate, producing a mixed quarter despite strong China-driven growth. Management indicated strong year-over-year growth is expected in Q3 excluding the $25.9 million one-time Q3 2025 order and is planning for growth in Q4, but provided no formal numeric guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue beat estimates
- Revenue was $93.5 million, up approximately 112.5% from $44.0 million in Q2 2025 but down approximately 0.5% from $94.0 million in Q1 2026; revenue exceeded the $90.6 million consensus estimate by approximately $2.9 million.
- Margins improved
- Gross margin was 74.5%, up 0.9 percentage points from 73.6% in Q1 2026 and 0.5 points from 74.0% in Q2 2025. Operating margin improved to 10.8% from 8.5% sequentially and negative 67.6% year over year.
- EPS turned higher but missed
- GAAP diluted EPS was $0.16, up from $0.10 in Q1 2026 and $(0.34) in Q2 2025, but below the $0.19 consensus estimate by $0.03.
- China drove growth
- China revenue was $52.3 million and was identified as the principal driver of the year-over-year revenue increase.
- Near-term growth outlook remains positive
- Management expects strong year-over-year Q3 growth even excluding the $25.9 million one-time order in Q3 2025, and is planning for year-over-year growth in Q4.
- Controls remained effective
- Disclosure controls were assessed as effective as of July 3, 2026, and there were no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- China concentration
- China revenue was $52.3 million, representing a substantial concentration of quarterly sales and increasing exposure to China demand, regulatory, and geopolitical conditions.
- Difficult comparison distortion
- The company’s Q3 comparison excludes a $25.9 million one-time Q3 2025 order, making reported year-over-year growth sensitive to the treatment of that order and potentially masking underlying demand trends.
- No updated risk-factor disclosure
- The filing states that no material changes in market risk occurred during the six months ended July 3, 2026; however, the company remains exposed to the market and operating risks described in the January 2, 2026 Form 10-K.
- Product and regulatory claims
- The company is involved in legal proceedings, claims, regulatory actions, and product-liability or medical-device-quality matters in the ordinary course; although no known claim is expected to materially affect results, unexpected outcomes could cause significant financial harm.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.16
- Gross margin
- 74.5%
- Operating margin
- 10.8%
- Segment
- China revenue: $52.3 million, a primary driver of year-over-year growth
- Segment
- Other segment revenue: not disclosed in the provided filing extract
What they said about what is next.
No formal numeric EPS or revenue guidance was provided. Management expects strong year-over-year growth in Q3 excluding the $25.9 million one-time Q3 2025 order and is planning for year-over-year growth in Q4.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- STAAR Surgical reported a robust Q1 2026 with net sales of $93.5 million, a significant 119.6% increase year-over-year, indicating a strong recovery. The company achieved net income of $5.2 million or $0.10 per diluted…
- 10-K · March 3, 2026
- STAAR Surgical describes a focused, product-led strategy centered on its EVO family of Implantable Collamer Lenses (ICLs) and reports that for the fiscal year ended January 2, 2026 approximately 100% of net sales were…
- 10-Q · November 5, 2025
- STAAR reported Q3 net sales of $94,732,000, up from $88,590,000 in the year-ago quarter, with gross margin expanding to 82.2% and operating income rising to $18,490,000. Diluted EPS was $0.18 (vs. $0.20 a year ago) and…
- 10-Q · August 6, 2025
- STAAR reported Q2 net sales of $44,320,000 and GAAP diluted loss per share of $0.34, with an operating loss of $29,964,000 (74.0% gross margin). Results improved versus the prior quarter (revenue +$1.32M, EPS improved…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing STAA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever